Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.36 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.36 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21982078 | 0.84 | KDM4E (0.50) | PRKCISREBF1SREBF2CYP3A4CYP2D6 | |
| SCHEMBL23624134 | 0.82 | PRKCI (0.48) | PRKCICYP1A2POLBTERTSREBF1 | |
| SCHEMBL11615543 | 0.82 | PRKCI (0.38) | PRKCICYP1A2POLBGRIN2DGRIN3B | |
| SCHEMBL10883653 | 0.82 | JAK2 (0.41) | PRKCICYP1A2POLBGRIN2DGRIN3B | |
| SCHEMBL14185014 | 0.80 | PRKCI (0.47) | PRKCICYP1A2POLBTERTSREBF1 | |
| Hydrochloric Acid SCHEMBL10883137 | 0.80 | GRIN2D (0.35) | PRKCIGRIN2DGRIN3BCHRM1ADRA1D | |
| SCHEMBL15880501 | 0.77 | PRKCI (0.62) | PRKCICYP1A2POLBTERTLMNA | |
| Dimethylamine SCHEMBL7744073 | 0.77 | NOS3 (0.55) | PRKCICYP1A2POLBSREBF1SREBF2 | |
| SCHEMBL23015823 | 0.76 | PRKCI (0.61) | PRKCICYP1A2POLBSREBF2GRIN2D | |
| SCHEMBL10966546 | 0.74 | PRKCI (0.52) | PRKCICYP1A2POLBTERTCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-07-04 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2023-11-02 | — | — | US | disclosed |
| CN-113950473-A | Next generation modulators of interferon gene Stimulators (STING) | 雷沃医疗有限公司 | 2022-01-18 | — | — | CN | disclosed |
| CN-102421777-A | Azacyclospiro derivatives as HSL inhibitors | HOFFMANN LA ROCHE | 2012-04-18 | — | — | CN | disclosed |
| CN-1972926-B | Indole derivatives as histamine receptor antagonists | HOFFMANN LA ROCHE | 2011-02-16 | — | — | CN | disclosed |
| CN-1972926-A | Indole derivatives as histamine receptor antagonists | HOFFMANN LA ROCHE (CH) | 2007-05-30 | — | — | CN | disclosed |
| CN-1468227-A | Non-imidazole aryloxyalkylamines | ����-������ҩƷ��˾ | 2004-01-14 | — | — | CN | disclosed |
| CN-1311773-A | Neuropeptide Y5 receptor antagonists | SCHERING CORP (US) | 2001-09-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216355-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN THE PREVENTION AND TREATMENT OF A DISEASE OR DISORDER CAUSED BY OR ASSOCIATED WITH ONE OR MORE PREMATURE TERMINATION CODONS | UPF1, NSUN2, RTF2 | PRKCI 1659/4885CYP1A2 1677/4885POLB 595/4885 |
| US-20230348418-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | PRKCI 2340/4885CYP1A2 170/4885POLB 4022/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | PRKCI 2386/4885CYP1A2 146/4885POLB 3996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.